ACLID, INC.

ACLID, INC. specializes in biotechnology research and development, with a focused expertise in nucleotide sequencing technologies and genomic data analysis. The company conducts foundational R&D to advance molecular diagnostics and bioinformatics platforms, particularly in support of defense-related biological threat detection and characterization. Their technical capabilities encompass high-throughput sequencing workflows, sequence alignment algorithms, and bioinformatic pipeline development for non-nano biotech applications, positioning them as a niche provider of genomic intelligence solutions for mission-critical government programs. ACLID’s approach emphasizes rapid prototyping and validation of sequencing methodologies tailored to field-deployable environments, distinguishing them through domain-specific adaptation of next-generation sequencing (NGS) tools. The contractor has demonstrated direct engagement with the Department of Defense, delivering research services under the Small Business Innovation Research (SBIR) program. Their work supports defense biodefense initiatives, including pathogen identification, genomic surveillance, and molecular signature development for biological agent characterization. This relationship reflects a pattern of collaboration on early-stage, high-risk R&D projects that bridge civilian biotech innovation and military operational needs. ACLID’s primary industry focus is in NAICS 541714—Research and Development in Biotechnology (excluding Nanobiotechnology)—where they apply molecular biology, computational genomics, and data-driven analysis to solve complex biological problems. Their vertical specialization lies in nucleic acid sequencing for defense and public health security applications, serving a market that values precision, reproducibility, and rapid turnaround in genomic research. ACLID, INC. is a small business structured as a 2L entity, headquartered in Staten Island, New York. The company holds no formal government certifications but leverages technical agility and domain-specific expertise to compete in federal R&D markets. Their geographic footprint is centralized, with operations aligned to support DoD-funded research initiatives through academic and government laboratory partnerships.